Comparative modeling of uterine cancer - uterine cancer is one of the few cancers for which incidence and mortality are both rising
Active Cooperative Agreement Awarded
- Award ID
- U01CA319216
- Recipient
-
Tufts Medical Center Parent, Inc. UEI MY2ERHGDV956
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,270,995
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 3% complete
- Place of performance
- Boston, MA 02111, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded Tufts Medical Center Parent, Inc., doing business as Tufts Medical Center, a Cooperative Agreement (U01CA319216) totaling $1.270995 million on September 17, 2026, under Assistance Listing 93.393, Cancer Cause and Prevention Research. The parent program supports research to identify cancer risks, risk-reduction strategies, and prevention mechanisms.
The award funds comparative modeling of uterine cancer, a cancer whose incidence and mortality are both rising and for which no routinely used screening or prevention strategies exist. The recipient will refine and apply three previously developed, calibrated, and validated population-level natural history models of uterine cancer to clinical scenarios in which decision-making is uncertain. Planned work includes exploring how secular changes in epidemiologic risk factors, including rising obesity and declining hysterectomy rates, influence current and future incidence and mortality; assessing primary and secondary prevention strategies; evaluating strategies to improve early diagnosis and timely treatment; and comparing health and economic outcomes of available and emerging therapeutic strategies.
Performance runs from the September 17, 2026 award date through an ultimate completion date of August 31, 2031. Place of performance is Boston, MA 02111.
Description
From 2019-2023, mortality from uterine cancer increased on average by 1.4% annually, the largest mortality increase for any female cancer and the only cisnet cancer site with increasing mortality. Despite the growing burden of uterine cancer in the U.S., the disease remains understudied and cancer control efforts have lagged. There are currently no routinely utilized screening or PREVENTION strategies. With the rise of more aggressive histologic subtypes associated with decreased survival, the timeliness of diagnosis and access to care have taken on increased urgency, yet guidance is lacking to expedite these. Similarly, despite the increasing availability and uptake of new treatments, decision-making to guide the molecular profiling and precision treatment of uterine cancer is not yet standardized. Finally, as uterine cancer incidence and death rise disproportionately among women under age 50, there is a need to better understand the tradeoffs inherent to decisions about fertility-sparing treatment approaches. To explore population-level effects of cancer control and PREVENTION activities, we previously developed, calibrated and validated three natural history models of uterine cancer. In this cisnet uterine cancer proposal, we will refine and apply these calibrated population-level natural history models to clinical scenarios in which decision-making is uncertain. First, we will explore how secular changes in epidemiologic risk factors including the rising obesity rate and declining hysterectomy rate influence current and future incidence and mortality. Second, we will assess primary and secondary PREVENTION strategies. Third, we will evaluate strategies to improve early diagnosis and timely treatment. Fourth, we will compare health and economic outcomes of available and emerging therapeutic strategies. Finally, we will evaluate benefits and tradeoffs of fertility-conserving treatment in young women. The broad, long-term objectives of this work are (1) continuous refinement and expansion of comparative natural history models of uterine cancer; (2) use of these models to discern the causes of recent trends in uterine cancer incidence and mortality; and (3) estimation of the impact of strategies aimed at reducing incidence (PREVENTION) and improving survival (screening, diagnosis, treatment) on future cancer burden. At the completion of this work, these data will be widely disseminated to patients and providers and have the potential to significantly impact the clinical care of women with uterine cancer and to guide cancer control strategies. Further, these models will serve as an invaluable resource for the uterine cancer community as new clinical questions and challenges emerge.
Quick answers
Who received award U01CA319216?
U01CA319216 was awarded to Tufts Medical Center Parent, Inc. by National Cancer Institute (National Institutes of Health) on September 17, 2026.
How much is award U01CA319216 worth?
$1,270,995 has been obligated on U01CA319216.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award